A detailed history of Mufg Securities Emea PLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mufg Securities Emea PLC holds 21,000 shares of VRTX stock, worth $10.2 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares
21,000
Holding current value
$10.2 Million
% of portfolio
0.38%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$460.0 - $505.78 $9.66 Million - $10.6 Million
21,000 New
21,000 $9.77 Million
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $12.9 Million - $15.3 Million
-50,496 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $11.4 Million - $14.9 Million
50,496 New
50,496 $14.7 Million
Q1 2020

May 12, 2020

SELL
$199.77 - $247.81 $2 Million - $2.48 Million
-10,000 Closed
0 $0
Q4 2019

Feb 11, 2020

BUY
$166.71 - $223.91 $1.67 Million - $2.24 Million
10,000 New
10,000 $2.19 Million
Q3 2019

Nov 12, 2019

SELL
$166.23 - $187.09 $9.04 Million - $10.2 Million
-54,400 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$164.61 - $190.37 $4.18 Million - $4.84 Million
25,400 Added 87.59%
54,400 $9.98 Million
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $4.75 Million - $5.65 Million
29,000 New
29,000 $5.34 Million
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $1.05 Million - $1.33 Million
-6,928 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$167.73 - $192.74 $1.11 Million - $1.28 Million
6,643 Added 2330.88%
6,928 $1.34 Million
Q2 2018

Aug 01, 2018

SELL
$145.72 - $169.96 $5.79 Million - $6.75 Million
-39,715 Reduced 99.29%
285 $48,000
Q3 2017

Nov 09, 2017

BUY
$148.13 - $162.24 $5.93 Million - $6.49 Million
40,000
40,000 $6.08 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $124B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mufg Securities Emea PLC Portfolio

Follow Mufg Securities Emea PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mufg Securities Emea PLC, based on Form 13F filings with the SEC.

News

Stay updated on Mufg Securities Emea PLC with notifications on news.